Skip to main content
Signal8

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

$BCLIPress releaseMay 28, 2026, 7:45 AM ETRead the release

BrainStorm Cell Therapeutics appointed Peter J. Pitts, former FDA Associate Commissioner, to its Board of Directors effective immediately. The appointment coincides with the company's preparation to initiate a Phase 3b ENDURANCE trial for its lead ALS therapy, NurOwn, under a Special Protocol Assessment (SPA) with the FDA.

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.